Dr. Philippe Pouletty, MD, is a Chairman at Abivax SA, a Chief Executive Officer & Director at Truffle Capital SAS and a Manager at Nakostech SARL.
He is on the Board of Directors at Plasmaprime SAS, Carmat SA, Deinove SA, Vexim SA, Truffle Capital SAS, Association Marie Lannelongue, Biokinesis SAS, Centre Chirurgical Marie Lannelongue, Deinobiotics SAS, Kephalios SAS, MyoPowers Medical Technologies France SAS and Pharnext SA. Dr. Pouletty was previously employed as a Member-Supervisory Board by Innate Pharma SA, a Chairman by France Biotech Association, a Founder by DrugAbuse Sciences SAS, a Chairman by SangStat Medical Corp., a Founder by Sangstat Pharmaceuticals Corp., a Member by Conseil Stratégique pour l'Innovation, a Member-Supervisory Board by Cytomics Pharmaceuticals SA, a Chairman by Splicos SAS, a Member by Strategic Council on Business Attractiveness, and a Vice Chairman by The European Association for Bioindustries.
He also served on the board at Altimmune, Inc. /Old/, Carbios SA, Theraclion SA, Neovacs SA, ConjuChem Biotechnologies, Inc., Diaccurate SASU, Drugabuse Sciences, Inc., Immune Targeting Systems (ITS) Ltd., Symetis SA, Theradiag SA and Wittycell SAS.
He received his doctorate degree from Université Pierre et Marie Curie and a doctorate degree from École Nationale Supérieure des Mines de Paris.